SPOTLIGHT: Ceragenix explains a delay

Beware great expectations. Denver-based Ceragenix Pharmaceuticals has issued a press release to explain why certain expectations of an outlicensing deal for EpiCeram haven't been met. "To be sure, it has taken longer to complete a licensing deal than we had anticipated," said CEO Steven Porter. "Several of the potential partners we were in discussions with (those furthest along in the process) had management and/or corporate changes that have delayed or eliminated the possibility of completing a transaction with them. We are in continuing discussions with several other potential marketing partners, and remain hopeful that we will complete an out-license transaction for EpiCeram in time to allow for commercialization during the first half of 2008." Release

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.